Feedback PLC Drug Trial and Trading Update (5975L)
29 April 2015 - 8:01AM
UK Regulatory
TIDMFDBK
RNS Number : 5975L
Feedback PLC
29 April 2015
29 April 2015
Feedback plc
("Feedback" or the "Company")
Drug trial and Trading update
Feedback plc (AIM: FDBK), the medical imaging software company,
notes that TexRAD, its texture analysis software product will be
used by Imaging Endpoints II, LLC, its exclusive partner, for
imaging core lab purposes in a forthcoming drug trial in the United
States. A study will shortly be commenced of colorectal cancer
patients (Stage IIIc) with either Regorafenib or Standard of Care
(No Treatment) after adjuvant FOLFOX. The Sponsor is US Oncology
Research and the Collaborator is Bayer Healthcare Pharmaceuticals,
Inc./Bayer Schering Pharma.
Trading Update
Following the recent announcements of new sales of TexRAD, the
Company announces an update on current trading.
Revenue for the current financial year ending May 2015 is
expected to be in line with market expectations however due to
contractual settlement costs, the product sales mix and the timing
of the revenue recognition from the new TexRAD sales, the loss for
the year will be higher than the current market expectations.
We continue to seek to broaden the Company's profile in the
medical imaging software sector and are in active discussions with
a number of potential customers for research versions of the TexRad
product.
We continue to manage our limited working capital resources so
as to maximise opportunities with customers and also to continue to
develop the Company's products.
For further information contact:
Feedback plc
Simon Barrell / Trevor Brown Tel: 01954 718072
/ Tom Charlton
Sanlam Securities UK (Nominated
Adviser and Joint Broker)
Simon Clements / Virginia Bull Tel: 020 7628 2200
Peterhouse Corporate Finance
Ltd (Joint Broker)
Lucy Williams / Duncan Vasey Tel: 020 7469 0936
This information is provided by RNS
The company news service from the London Stock Exchange
END
STRUWRNRVKASUAR
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024